Cempra, Inc. (CEMP - Free Report) was a big mover last session, as the company saw its shares increase more than 6% on the day. The move came on the back of solid volume too, as far more shares changed hands than in a normal session. This continues the recent uptrend for this drug company as the stock is now up nearly 28% in the past one month time frame.
The company has seen 4 positive estimate revisions in the past few weeks and its earnings consensus has moved up over the past two months, suggesting that more solid trading could be ahead for CEMP. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Cempra currently has a Zacks Rank #2 (Buy) and its Earnings ESP is 0.00%.
Other bio-tech stocks worth considering include Jazz Pharmaceuticals Public Limited Company (JAZZ - Free Report) , Lannett Company, Inc. (LCI - Free Report) and Apricus Biosciences, Inc. (APRI - Free Report) . All these carry the same Zacks Rank as Cempra.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>